相关实验视频

Updated: May 9, 2026

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

设计基于的乙-CoA合成酶2抑制剂的计算方法:抗癌开发的新视野

Musab Ali¹, Ernest Oduro-Kwateng¹, Ibrahim Oluwatobi Kehinde¹

¹Molecular Bio-Computation and Drug Design Research Group, School of Health Sciences, University of KwaZulu Natal, Westville Campus, Durban, South Africa.

Cell biochemistry and biophysics

|April 26, 2025

概括

研究人员设计了一种新型的抑制剂Pep16,用于乙-A合成酶2 (ACSS2),这是癌症的关键标. 计算方法确定了Pep16,显示出优越的结合亲和力和作为抗癌药物发现的特定ACSS2抑制剂的潜力.

科学领域:

生物化学生物化学
计算生物学计算生物学
药物发现药物发现药物发现

背景情况:

乙-CoA合成酶2 (ACSS2) 在各种瘤中高度表达,增强恶性瘤并代表一种新的抗癌标.
与传统治疗方法相比,酸衍生药物提供了更好的选择性和有效性.

研究的目的:

通过计算设计一种针对ACSS2的新型抑制剂,用于潜在的抗癌应用.
确定具有高结合亲和力和有利的治疗性质的类候选者.

主要方法:

基于ACSS2核酸基因生成了3600个序列,将氨基酸分为六个生理化学组.
采用了新的建模,支持矢量机过器,结构预测,分子对接,分子动力学模拟和MM/GBSA分析.
通过严格的计算选和验证,确定Pep16是顶级候选者.

主要成果:

与已知的抑制剂 (53.7 ± 0.7 kcal / mol) 相比,Pep16显示出明显更高的结合亲和力 (91.1 ± 1.6 kcal / mol).
分子动力学揭示Pep16增强了ACSS2的构造变异性,占据了更大的结合接口,并形成了坚定的相互作用,特别是与关键残留物如ARG 373,ARG 526,ARG 628,ARG 631和LYS 632.
16锁定了ACSS2核酸口袋,可能抑制ATP结合和催化活性.

结论:

16是一种有前途的,特定的ACSS2抑制剂,通过系统计算方法确定.
开发的方法作为未来基于的药物发现的有价值的工具.
需要进一步的研究来确认Pep16的治疗潜力,并将其与现有的抑制剂进行比较.

关键词:

在ACSS2中使用ACSS2.抗癌剂是一种抗癌剂.分子对接是分子对接.分子动力学模拟的模拟.类抑制剂类抑制剂

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

Phase II Reactions: Acetylation Reactions

Phase II Reactions: Acetylation Reactions

Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...